Read by QxMD icon Read

overall survival breast cancer

Hye Jin Kim, Eunyoung Kang, Jee Hyun Kim, Se Hyun Kim, Yu Jung Kim, In Ah Kim, Keun-Yong Eom, Su Min Chae, Kyu Min Kang, Eun Kyu Kim, Sung-Won Kim
BACKGROUND: Several studies have suggested that primary tumor removal improved overall survival for patients with stage IV breast cancer. However, the survival benefit of local treatment remains controversial. The purpose of the present study was to determine whether surgical removal of the primary tumor provides survival benefits to patients with stage IV breast cancer. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 155 patients with an initial diagnosis of stage IV breast cancer at Seoul National University Bundang Hospital from 2003 to 2014...
May 28, 2018: Clinical Breast Cancer
J Zhang, Y Lin, X J Sun, B Y Wang, Z H Wang, J F Luo, L P Wang, S Zhang, J Cao, Z H Tao, J Wu, Z M Shao, W T Yang, X C Hu
Background: CBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel plus gemcitabine (GT) regimen as first-line treatment of metastatic triple-negative breast cancer (mTNBC). This study focused on the updated survival data and the explorations of potential biomarkers for efficacy. Patients and methods: Germ-line mutations of homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients...
June 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Trygve Lofterød, Elin S Mortensen, Hawa Nalwoga, Tom Wilsgaard, Hanne Frydenberg, Terje Risberg, Anne Elise Eggen, Anne McTiernan, Sura Aziz, Erik A Wist, Andreas Stensvold, Jon B Reitan, Lars A Akslen, Inger Thune
BACKGROUND: High triglycerides and low levels of high density lipoprotein (HDL)-cholesterol are observed to promote tumor growth. However, whether breast cancer heterogeneity may explain the contradictory influence of triglycerides and cholesterol observed on breast cancer prognosis remains unclear. METHODS: A population-based survival study among 464 breast cancer cases identified within the Tromsø study was conducted. Pre-diagnostic triglycerides, total-cholesterol and HDL-cholesterol were measured, and detailed clinical and histopathological data were obtained...
June 15, 2018: BMC Cancer
Shuzhen Lv, Yunchao Wang, Tao Sun, Donggui Wan, Lijun Sheng, Wei Li, Huayun Zhu, Yanping Li, Janice Lu
No abstract text is available yet for this article.
June 15, 2018: Oncology Research and Treatment
Susanne Oksbjerg Dalton, Nis Palm Suppli, Marianne Ewertz, Niels Kroman, Luigi Grassi, Christoffer Johansen
OBJECTIVES: To investigate overall and breast cancer-specific mortality in early-stage breast cancer patients with and without schizophrenia or related disorders. METHODS: We used Danish national registers to identify all women with no prior history of cancer or organic mental disorders, who were diagnosed with early-stage breast cancer 1995-2011. Logistic regression models were used to calculate the odds ratios (ORs) for not being allocated to guideline treatment...
June 11, 2018: Breast: Official Journal of the European Society of Mastology
Tao Zuo, Parker Wilson, Ali Fuat Cicek, Malini Harigopal
Androgen receptor (AR) expression is an emerging prognostic marker that has been observed in 25% to 75% of triple negative breast cancers (TNBCs) that lack estrogen receptor, progesterone receptor and HER2 overexpression. TNBCs are treated with AR-targeted therapies and standardized evaluation of AR expression may help guide patient management. Basal-like TNBCs are a subgroup of TNBCs defined by positive immunoreactivity for CK5/6 or EGFR that carry a worse prognosis. However, it's unclear whether basal-like TNBCs have a different rate of AR positivity or if AR expression is predictive of disease free survival in this patient group...
June 11, 2018: Human Pathology
Fararjeh-Salah Abdul Fattah, Shih-Hsin Tu, Li-Ching Chen, Yun-Ru Liu, Yen-Kuang Lin, Hang-Lung Chang, Hui-Wen Chang, Chih-Hsiung Wu, Wendy-Hwang Verslues, Yuan-Soon Ho
The transcription factor GATA3 plays a significant role in mammary gland development and differentiation. We analyzed expression of GATA3 in breast cancer (BC) cell lines and clinical specimens from BC patients in Taiwan. Semi-quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR), quantitative real-time PCR carried out to determine the mRNA level of GATA3 from 241 pairs of matched tumor and adjacent normal tissues from anonymous female donors. GATA3 immunohistochemistry (IHC) staining and H-score were performed (n=25)...
June 11, 2018: Human Pathology
Ziyi Yu, Longquan Lou, Yi Zhao
Fibroblast growth factor 18 (FGF18) increases cell motility and invasion in colon tumors, and is linked with ovarian and lung tumors. Furthermore, the increased expression of FGF18 mRNA and protein has been associated with poor overall survival in cancer patients. However, its function has not been investigated in breast cancer. In the present study, we demonstrated that FGF18 promoted cell growth and metastasis in vitro and stimulated tumor growth in xenograft models in vivo. FGF18 mediated the proliferation of MDA‑MB‑231 cells via the ERK/c‑Myc signaling pathway and induced epithelial‑to‑mesenchymal transition (EMT) factors to promote cancer migration and invasion...
June 7, 2018: Oncology Reports
Wei Zhao, Xingwang Kuai, Xueyi Zhou, Lizhou Jia, Jinsong Wang, Xiaobing Yang, Zhidan Tian, Xiaolei Wang, Qian Lv, Bin Wang, Youcai Zhao, Wenbin Huang
Trop2 is considered to have an important function in tumor metastasis and the promotion of epithelial‑mesenchymal transition (EMT). E‑cadherin is a crucial factor in intercellular adhesion and EMT transformation. In the present study, we detected the expression of Trop2 and E‑cadherin in breast cancer (BC) to better define their prognostic value. The mRNA expression levels of these two genes in 20 cases of fresh BC tissues were detected by quantitative real‑time polymerase chain reaction (qRT‑PCR)...
June 14, 2018: Oncology Reports
Joe Yeong, Jeffrey Chun Tatt Lim, Bernett Lee, Huihua Li, Noel Chia, Clara Chong Hui Ong, Weng Kit Lye, Thomas Choudary Putti, Rebecca Dent, Elaine Lim, Aye Aye Thike, Puay Hoon Tan, Jabed Iqbal
Breast cancer is the most common malignancy affecting women, but the heterogeneity of the condition is a significant obstacle to effective treatment. Triple negative breast cancers (TNBCs) do not express HER2 or the receptors for estrogen or progesterone, and so often have a poor prognosis. Tumor-infiltrating T cells have been well-characterized in TNBC, and increased numbers are associated with better outcomes; however, the potential roles of B cells and plasma cells have been large. Here, we conducted a retrospective correlative study on the expression of B cell/plasma cell-related genes, and the abundance and localization of B cells and plasma cells within TNBCs, and clinical outcome...
2018: Frontiers in Immunology
Erin D Giles, Sonali Jindal, Elizabeth A Wellberg, Troy Schedin, Steven M Anderson, Ann D Thor, Dean P Edwards, Paul S MacLean, Pepper Schedin
BACKGROUND: Obesity and type II diabetes are linked to increased breast cancer risk in postmenopausal women. Patients treated with the antidiabetic drug metformin for diabetes or metabolic syndrome have reduced breast cancer risk, a greater pathologic complete response to neoadjuvant therapy, and improved breast cancer survival. We hypothesized that metformin may be especially effective when targeted to the menopausal transition, as this is a lifecycle window when weight gain and metabolic syndrome increase, and is also when the risk for obesity-related breast cancer increases...
June 14, 2018: Breast Cancer Research: BCR
Deep Shah, Debra Wyatt, Andrew Baker, Patricia Simms, Daniel S Peiffer, Michelle L Fernandez, Emad A Rakha, Andrew R Green, Aleksandra Filipovic, Lucio Miele, Clodia Osipo
PURPOSE: Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer is driven by cells possessing stem-like properties of self-renewal and differentiation, referred to as Cancer Stem Cells (CSCs). CSCs are implicated in radiotherapy, chemotherapy resistance, and tumor recurrence. Notch promotes breast CSCs survival and self-renewal, and overexpression of Notch1 and the Notch ligand Jagged1 predict poor outcome. Resistance to anti-HER2 therapy in HER2+ breast cancer requires Notch1, and that combination of trastuzumab and a Gamma Secretase Inhibitor (GSI) prevents tumor relapse in xenograft models...
June 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Karen A Cadoo, Peter A Kaufman, Andrew D Seidman, Cassandra Chang, Dongyuan Xing, Tiffany A Traina
BACKGROUND: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ≥ 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer. PATIENTS AND METHODS: Patients with human epidermal growth factor receptor 2-negative, stage I to III breast cancer received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1...
April 7, 2018: Clinical Breast Cancer
Jun Ni, Yun Peng, Fu-Lan Yang, Xun Xi, Xing-Wei Huang, Chun He
Introduction: The aim of this study was to evaluate the expression of C-type lectin domain family 3 member A (CLEC3A) and its clinical significance in breast invasive ductal cancer (IDC) as well as its effect on breast cancer (BC) cell proliferation and metastasis. In this study, the level of CLEC3A expression in The Cancer Genome Atlas (TCGA) datasets was analyzed. Materials and methods: Clinical collected samples and BC cells were measured using quantitative reverse transcription polymerase chain reaction...
2018: OncoTargets and Therapy
Kang Wang, Qiu-Juan Wang, Yong-Fu Xiong, Yang Shi, Wen-Jing Yang, Xiang Zhang, Hong-Yuan Li
We aimed to compare the overall survival (OS) and standardized mortality rate (SMR) of the male breast cancer (MBC) with female breast cancer (FBC) after propensity score matching. Based on the Surveillance, Epidemiology, and End Results (SEER), the early breast cancer patients (T1-2 N0-2 M0 ) were extracted from 1998-2007. This study included 1,111 and 2,151 patients with early MBC and FBC, respectively, whose clinicopathological characteristics were well balanced. At a mean follow-up time of 97 months, 10-year OS rate was 58...
June 11, 2018: Scientific Reports
Traci LeMasters, S Suresh Madhavan, Usha Sambamoorthi, Hannah W Hazard-Jenkins, Kimberly M Kelly, Dustin Long
Background: This study examined receipt of guideline-concordant care (GCC) according to evidence-based treatment guidelines and quality measures and specific types of treatment among older women with breast cancer. Patients and Methods: A total of 142,433 patients aged ≥66 years diagnosed with stage I-III breast cancer between 2007 and 2011 were identified in the SEER-Medicare linked database. Algorithms considering cancer characteristics and the appropriate course of care as per guidelines versus actual care received determined receipt of GCC...
June 2018: Journal of the National Comprehensive Cancer Network: JNCCN
Charly Ryan Good, Shoghag Panjarian, Andrew D Kelly, Jozef Madzo, Bela Patel, Jaroslav Jelinek, Jean-Pierre J Issa
Both gains and losses of DNA methylation are common in cancer, but the factors controlling this balance of methylation remain unclear. Triple-negative breast cancer (TNBC), a subtype that does not overexpress hormone receptors or HER2/NEU, is one of the most hypomethylated cancers observed. Here we discovered that the TET1 DNA demethylase is specifically overexpressed in about 40% of patients with TNBC, where it is associated with hypomethylation of up to 10% of queried CpG sites and a worse overall survival...
June 11, 2018: Cancer Research
Petra Wirtz, Freerk T Baumann
The current scientific field of exercise interventions in breast cancer is very large. Rehabilitation focuses on restoring or improving quality of life and thus on independence and participation in life. Hence, it is important to investigate exercise interventions in the setting of rehabilitation and aftercare. It is also necessary to determine the influence of physical activity or exercise therapy on the prevention of recurrence and mortality as well as on certain side effects of the disease and its medical treatment in rehabilitation...
April 2018: Breast Care
Daniel Rayson, Jennifer I Payne, James C R Michael, Kaitlyn M Tsuruda, Mohamed Abdolell, Penny J Barnes
BACKGROUND: Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to examine survival outcomes. PATIENTS AND METHODS: All women with a diagnosis of primary TNBC between January 1, 2005, and December 31, 2012, in Nova Scotia, Canada, were included...
April 28, 2018: Clinical Breast Cancer
Yarely M Salinas-Vera, Laurence A Marchat, Raúl García-Vázquez, Claudia Haydée González de la Rosa, Eduardo Castañeda-Saucedo, Napoleón Navarro Tito, Carlos Palma Flores, Carlos Pérez-Plasencia, José L Cruz-Colin, Ángeles Carlos-Reyes, José Sullivan López-González, María Elizbeth Álvarez-Sánchez, César López-Camarillo
RNA-based multi-target therapies focused in the blocking of signaling pathways represent an attractive approach in cancer. Here, we uncovered a miR-204 cooperative targeting of multiple signaling transducers involved in vasculogenic mimicry (VM). Our data showed that invasive triple negative MDA-MB-231 and Hs-578T breast cancer cells, but not poorly invasive MCF-7 cells, efficiently undergoes matrix-associated VM under hypoxia. Ectopic restoration of miR-204 in MDA-MB-231 cells leads to a potent inhibition of VM and reduction of number of branch points and patterned 3D channels...
June 6, 2018: Cancer Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"